A pilot study of atorvastatin treatment in dyslipemid, n

Alimentary Pharmacology and Therapeutics
23, 1643-1647
DOI: 10.1111/j.1365-2036.2006.02926.x

Citation Report

#	Article	IF	Citations
1	Mechanisms underlying nonalcoholic steatohepatitis. Drug Discovery Today Disease Mechanisms, 2006, 3, 479-488.	0.8	8
3	Statins for non-alcoholic fatty liver disease: a new indication?. Alimentary Pharmacology and Therapeutics, 2006, 24, 698-699.	1.9	25
4	Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence. Scandinavian Journal of Gastroenterology, 2007, 42, 139-147.	0.6	17
5	Genotypic Resistance in HIV-Infected Naive Patients Receiving Abacavir Plus Lamivudine and Efavirenz. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 253-255.	0.9	2
6	Safety of Statin Therapy in HIV/Hepatitis C Virus-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 258-260.	0.9	13
7	No Evidence of Relation Between Peripheral Neuropathy and Presence of Hemochromatosis Gene Mutations in HIV-1-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 255-256.	0.9	8
9	Is Phosphatemia the Best Tool to Monitor Renal Tenofovir Toxicity?. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 256-258.	0.9	16
10	Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 2007, 191, 235-240.	0.4	500
11	Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance. Medical Clinics of North America, 2007, 91, 1125-1149.	1.1	136
12	Drug treatment and type 2 diabetes: the impact of liver disease. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 318-323.	0.2	1
13	Direct adipotropic actions of atorvastatin: Differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. European Journal of Pharmacology, 2007, 564, 37-46.	1.7	38
14	Current treatments in nonalcoholic steatohepatitis. Current Treatment Options in Gastroenterology, 2007, 10, 425-434.	0.3	5
15	Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International, 2007, 1, 343-354.	1.9	5
16	Hypertension and hepatic steatosis. Current Hypertension Reports, 2008, 10, 182-187.	1.5	3
17	Statins in liver disease: A molehill, an iceberg, or neither?. Hepatology, 2008, 48, 662-669.	3.6	117
18	Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabetic Medicine, 2008, 25, 523-529.	1.2	41
19	Review article: current management of nonâ€alcoholic fatty liver disease and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 2-12.	1.9	146
20	Review article: diagnosis and treatment of nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 503-522.	1.9	98

#	Article	IF	Citations
21	Safety of Statin Therapy in Patients with Preexisting Liver Disease. Pharmacotherapy, 2008, 28, 522-529.	1.2	40
22	Disease-Specific Mechanisms of Fibrosis: Hepatitis C Virus and Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2008, 12, 805-824.	1.0	28
23	Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism: Clinical and Experimental, 2008, 57, 1711-1718.	1.5	184
24	Diagnosis and Therapy of Nonalcoholic Steatohepatitis. Gastroenterology, 2008, 134, 1682-1698.	0.6	313
25	Evolving trends in nonalcoholic fatty liver disease. European Journal of Internal Medicine, 2008, 19, 75-82.	1.0	31
27	Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacological Reviews, 2008, 60, 311-357.	7.1	346
28	Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Review of Cardiovascular Therapy, 2008, 6, 369-383.	0.6	18
29	Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem. European Journal of Gastroenterology and Hepatology, 2008, 20, 1002-1005.	0.8	2
31	Liver biochemistry abnormalities in a quaternary care lipid clinic database. Annals of Hepatology, 2008, 7, 63-66.	0.6	3
32	Treatment regimens for non-alcoholic fatty liver disease. Annals of Hepatology, 2009, 8, S51-S59.	0.6	42
33	Nonalcoholic Fatty Liver Disease in Pediatric Patients. Obesity Management, 2009, 5, 65-71.	0.2	0
34	The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therapeutic Advances in Gastroenterology, 2009, 2, 157-163.	1.4	129
35	Drug-Induced Liver Injury Associated with Statins. Seminars in Liver Disease, 2009, 29, 412-422.	1.8	132
36	Nonviral Hepatitis. Journal of Pharmacy Practice, 2009, 22, 388-404.	0.5	5
37	Review: Current status of therapy in nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2009, 2, 29-43.	1.4	11
38	A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 241-251.	1.4	22
39	Nonâ€alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews, 2010, 11, 430-445.	3.1	161
40	Current treatment of nonâ€alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2009, 11, 188-195.	2.2	70

#	Article	IF	Citations
41	Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management. Clinics in Liver Disease, 2009, 13, 249-266.	1.0	55
42	Recurrent nonviral liver disease following liver transplantation. Expert Review of Gastroenterology and Hepatology, 2009, 3, 257-268.	1.4	5
43	A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology, 2009, 43, 990-994.	1.1	248
44	The metabolic syndrome and nonalcoholic fatty liver disease in children. Current Opinion in Pediatrics, 2009, 21, 529-535.	1.0	75
45	Non-Alcoholic Fatty Liver Disease. , 0, , 119-134.		4
46	Nonalcoholic Steatohepatitis: A Review of the Literature and Updates in Management. Southern Medical Journal, 2010, 103, 547-550.	0.3	11
47	Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. Journal of Gastroenterology, 2010, 45, 750-757.	2.3	141
48	Nonalcoholic Fatty Liver Disease: A Review and Update. Digestive Diseases and Sciences, 2010, 55, 560-578.	1.1	287
49	Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. International Journal of Clinical Practice, 2010, 64, 968-983.	0.8	36
50	The role of adiponectin in the pathogenesis and treatment of nonâ€alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2010, 12, 365-383.	2.2	220
51	Prevention and treatment of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 331-340.	0.4	18
52	Pathogenesis of non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 71-83.	0.2	581
53	Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2010, 3, 121-137.	1.4	119
54	Review: Advances in the treatment of nonalcoholic fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism, 2010, 1, 101-115.	1.4	19
55	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Annals of Medicine, 2011, 43, 167-171.	1.5	39
56	3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: A therapeutic controversy. Journal of Clinical Lipidology, 2011, 5, 450-459.	0.6	35
57	Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial. American Journal of Gastroenterology, 2011, 106, 71-77.	0.2	214
58	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology, 2011, 27, 635-662.	0.8	160

#	Article	IF	Citations
59	Non-invasive prediction of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 498-499.	1.8	0
60	Reply to: â€œNon-invasive prediction of fibrosis in nonalcoholic fatty liver diseaseâ€•. Journal of Hepatology, 2011, 55, 499-500.	1.8	0
61	Pitavastatin inhibits hepatic steatosis and fibrosis in nonâ€•alcoholic steatohepatitis model rats. Hepatology Research, 2011, 41, 375-385.	1.8	32
62	Efficacy of pitavastatin for the treatment of nonâ€•alcoholic steatohepatitis with dyslipidemia: An openâ€•label, pilot study. Hepatology Research, 2011, 41, 1057-1065.	1.8	69
63	Association Between Fatty Liver and Cardiovascular Disease: Mechanism and Clinical Implications. , 0, , .		0
64	Abnormalities of Carbohydrate Metabolism and the Liver. , 2011, , 795-803.e4.		1
65	Lipid Targets During Statin Treatment in Dyslipidemic Patients Affected by Nonalcoholic Fatty Liver Disease. American Journal of the Medical Sciences, 2011, 342, 383-387.	0.4	16
66	Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2011, 13, 692-702.	2.2	92
67	Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicology and Applied Pharmacology, 2011, 251, 32-40.	1.3	54
68	Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. Digestive Diseases and Sciences, 2011, 56, 3439-3449.	1.1	78
69	Comparison of Dietary Control and Atorvastatin on High Fat Diet Induced Hepatic Steatosis and Hyperlipidemia in Rats. Lipids in Health and Disease, 2011, 10, 23.	1.2	63
70	Does adiponectin benefit steatotic liver transplantation?. Liver Transplantation, 2011, 17, n/a-n/a.	1.3	13
71	Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes/Metabolism Research and Reviews, 2011, 27, 54-62.	1.7	58
72	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs, 2011, 16, 121-136.	1.0	18
73	Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2011, 12, 1901-1911.	0.9	13
74	Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2011, 9, 287-290.	0.5	44
75	Effect of Atorvastatin, Vitamin E and C on Nonalcoholic Fatty Liver Disease: Is the Combination Required?. American Journal of Gastroenterology, 2011, 106, 78-80.	0.2	32
76	Treatment of Recurrent Nonviral Disease. , 2012, , 910-915.		0

#	Article	IF	Citations
77	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clinical Lipidology, 2012, 7, 471-481.	0.4	23
78	Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2012, 32, 022-029.	1.8	189
79	Way back for fructose and liver metabolism: Bench side to molecular insights. World Journal of Gastroenterology, 2012, 18, 6552.	1.4	39
80	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012, 142, 1592-1609.	0.6	1,486
81	Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology, 2012, 47, 1257-1266.	2.3	54
82	NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis, 2012, 220, 287-293.	0.4	79
83	Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	64
84	Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: A post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS). International Journal of Cardiology, 2012, 154, 362-365.	0.8	7
85	Normalization of ejection fraction in subjects with systolic heart failure. Is it really normal? A myocardial deformation study. International Journal of Cardiology, 2012, 154, 365-367.	0.8	8
86	Is rosuvastatin effective for nonâ€alcoholic steatohepatitis with dyslipidemia?. Hepatology Research, 2012, 42, 1055-1057.	1.8	0
87	Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. Journal of Clinical and Experimental Hepatology, 2012, 2, 156-173.	0.4	32
88	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-Î±-lowering property. Digestive and Liver Disease, 2012, 44, 492-496.	0.4	50
89	Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2012, 10, 837-858.	2.4	229
90	Nonalcoholic fatty liver disease: from lipid profile to treatment. Clinical Journal of Gastroenterology, 2012, 5, 313-321.	0.4	9
91	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Journal of Gastroenterology, 2012, 107, 811-826.	0.2	359
92	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55, 2005-2023.	3.6	2,935
93	Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies. Digestive Diseases and Sciences, 2012, 57, 1773-1781.	1.1	58
94	Efficacy of rosuvastatin for the treatment of nonâ€alcoholic steatohepatitis with dyslipidemia: An openâ€label, pilot study. Hepatology Research, 2012, 42, 1065-1072.	1.8	56

#	Article	IF	Citations
95	Statins in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Updated Review. Current Atherosclerosis Reports, 2013, 15, 305.	2.0	33
96	Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults. Pharmacotherapy, 2013, 33, 223-242.	1.2	13
97	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs, 2013, 73, 1-14.	4.9	139
98	Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The Cochrane Library, 2013, , CD008623.	1.5	71
99	Diet Quality. , 2013, , .		1
100	Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. International Journal of Molecular Sciences, 2013, 14, 22933-22966.	1.8	88
101	Emerging drugs for non-alcoholic steatohepatitis. Expert Opinion on Emerging Drugs, 2013, 18, 279-290.	1.0	13
102	A Novel Inhibitor of Stearoyl-CoA Desaturase-1 Attenuates Hepatic Lipid Accumulation, Liver Injury and Inflammation in Model of Nonalcoholic Steatohepatitis. Biological and Pharmaceutical Bulletin, 2013, 36, 259-267.	0.6	27
103	Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2013, 105, 409-420.	0.1	36
104	STATIN SAFETY REVISITED DATA. Rational Pharmacotherapy in Cardiology, 2013, 9, 143-148.	0.3	1
105	Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World Journal of Gastroenterology, 2014, 20, 12182.	1.4	51
106	Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8341.	1.4	61
107	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. Advances in Pharmacoepidemiology & Drug Safety, 2014, 03, .	0.1	1
108	Resistant Nonalcoholic Fatty Liver Disease Amelioration With Rosuvastatin and Pioglitazone Combination Therapy in a Patient With Metabolic Syndrome. Annals of Pharmacotherapy, 2014, 48, 137-141.	0.9	10
109	Management of fatty liver disease with the metabolic syndrome. Expert Review of Gastroenterology and Hepatology, 2014, 8, 487-500.	1.4	26
110	Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease. Archives of Medical Research, 2014, 45, 52-57.	1.5	15
111	Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet. Lipids in Health and Disease, 2014, 13, 22.	1.2	27
112	Potential Approaches to Ameliorate Hepatic Fat Accumulation Seen with MTP Inhibition. Drug Safety, 2014, 37, 213-224.	1.4	11

#	Article	IF	Citations
113	Benefitâ€"Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Safety, 2014, 37, 481-500.	1.4	4
114	Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America, 2014, 98, 55-72.	1.1	31
115	Lipid lowering in liver and chronic kidney disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 339-352.	2.2	9
116	Treating the patient with nonalcoholic fatty liver disease. Nurse Practitioner, 2015, 40, 36-42.	0.2	2
117	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology, 2015, 21, 6820-6834.	1.4	120
118	Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice, 2015, 2015, 1-14.	0.7	25
119	Non-alcoholic Fatty Liver Disease and Metabolic Syndromeâ€"Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. Journal of Clinical and Experimental Hepatology, 2015, 5, 51-68.	0.4	122
120	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2015, 21, 3777.	1.4	123
121	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2015, 47, 4-11.	0.4	121
122	Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterology, 2015, 15, 22.	0.8	69
123	Lipid Management. , 2015, , .		1
124	Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radical Research, 2015, 49, 1405-1418.	1.5	248
125	Nonalcoholic fatty liver disease and statins. Metabolism: Clinical and Experimental, 2015, 64, 1215-1223.	1.5	68
126	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. , 2015, , 149-173.		1
127	Statins and the Liver. Cardiology Clinics, 2015, 33, 257-265.	0.9	7
129	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterology Research and Practice, 2016, 2016, 1-17.	0.7	54
130	Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Frontiers in Immunology, 2016, 7, 490.	2.2	61
131	Hybrids of coumarinâ€"indole: design, synthesis and biological evaluation in Triton WR-1339 and high-fat diet induced hyperlipidemic rat models. MedChemComm, 2016, 7, 1858-1869.	3.5	5

#	Article	IF	Citations
132	Evaluation of Statin Treatment for Nonalcoholic Fatty Liver Disease. Journal of Pharmacy Technology, 2016, 32, 169-173.	0.5	6
133	Statins and the Liver. Endocrinology and Metabolism Clinics of North America, 2016, 45, 117-128.	1.2	11
134	Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2016, 20, 351-364.	1.0	13
136	The Fatty Liver Index (FLI) Relates to Diabetes-Specific Parameters and an Adverse Lipid Profile in a Cohort of Nondiabetic, Dyslipidemic Patients. Journal of the American College of Nutrition, 2017, 36, 287-294.	1.1	8
137	Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline. Experimental and Therapeutic Medicine, 2017, 13, 2375-2381.	0.8	34
138	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2950-2961.	1.8	66
139	(â€)â€Epigallocatechinâ€3â€gallate and atorvastatin treatment downâ€regulates liver fibrosisâ€related genes in nonâ€alcoholic fatty liver disease. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 1180-1191.	0.9	13
140	Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis. Digestive Disease Interventions, 2017, 01, 066-073.	0.3	0
141	Activation of hepatic Nogo-B receptor expressionâ€"A new anti-liver steatosis mechanism of statins. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 177-190.	1.2	13
142	Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases (Basel, Switzerland), 2018, 6, 87.	1.0	14
143	Safety and efficacy of statin therapy. Nature Reviews Cardiology, 2018, 15, 757-769.	6.1	239
144	Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Diseaseâ€™s Statin Therapy in Men. Advances in Pharmacological Sciences, 2018, 2018, 1-7.	3.7	9
145	The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Scientific Reports, 2018, 8, 12004.	1.6	19
146	Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2019, 17, 2769-2775.e4.	2.4	37
147	Statins in Females. Indian Journal of Cardiovascular Disease in Women WINCARS, 2019, 04, 099-106.	0.1	0
148	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis . Hepatic Medicine: Evidence and Research, 2019, Volume 11, 159-178.	0.9	33
149	Hepatoprotective Effects of a Novel Trihoney against Nonalcoholic Fatty Liver Disease: A Comparative Study with Atorvastatin. Scientific World Journal, The, 2020, 2020, 1-14.	0.8	2
150	Drugâ€Induced Liver Injury in GI Practice. Hepatology Communications, 2020, 4, 631-645.	2.0	47

#	Article	IF	Citations
151	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Translational Gastroenterology and Hepatology, 2021, 6, 60-60.	1.5	7
152	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients, 2021, 13, 2830.	1.7	27
153	High-intensity interval training with probiotic supplementation decreases gene expression of NF-Îºî2 and CXCL2 in small intestine of rats with steatosis. Sport Sciences for Health, 2022, 18, 491-497.	0.4	1
155	Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes. , 2013, , 61-73.		1
156	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. American Journal of Gastroenterology, 2021, 116, 116-124.	0.2	63
157	Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Asian Biomedicine, 2018, 12, 3-13.	0.2	5
158	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2013, 19, 325.	4.5	105
159	Liver Mitochondrial Respiratory Function and Coenzyme Q Content in Rats on a Hypercholesterolemic Diet Treated With Atorvastatin. Physiological Research, 2012, 61, 185-193.	0.4	12
160	Pathogenesis and management issues for non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2007, 13, 4539.	1.4	223
161	Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World Journal of Gastroenterology, 2014, 20, 12082.	1.4	155
162	Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2015, 21, 7008-7013.	1.4	67
163	Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi Journal of Gastroenterology, 2016, 22, 91.	0.5	29
164	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology, 2013, 5, 470.	0.8	124
165	Nutrition, Diet Therapy, and the Liver. , 0, , .		1
166	Using Parenteral Fish Oil In Nash. , 2009, , 81-95.		0
167	Clinical Aspects of Nonalcoholic Fatty Liver Disease. Oxidative Stress and Disease, 2014, , 3-24.	0.3	0
168	Non-alcoholic Fatty Liver Disease in Obesity. , 2016, , 159-179.		0
169	Non-Alcoholic Fatty Liver Disease. The Egyptian Journal of Hospital Medicine, 2018, 70, 570-576.	0.0	0

#	Article	IF	Citations
170	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology, 2022, 14, 119-139.	0.8	13
171	Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 7841.	1.8	13